secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001739104-24-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco reports Q4 net loss $141M, full-year loss $1.23B; cuts 420 jobs in restructuring
--------------------------------------------------------------------------------

- Q4 2023 revenue $1,035M (+5% YoY); reported net loss $141M ($0.29 EPS), adjusted EPS $0.08.
- Full-year 2023 revenue $4,417M (flat YoY); net loss $1,231M; adjusted EBITDA $979M; adjusted EPS $0.89.
- Full-year 2024 guidance: revenue $4,450-4,540M; adjusted EBITDA $960-1,010M; adjusted EPS $0.87-0.95.
- Restructuring eliminates ~420 positions; charges $50-55M in 2024, annualized savings $30-35M.
- Aqua business sale to Merck Animal Health for ~$1.3B expected mid-2024; proceeds to reduce debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/elan-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001739104-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer